Marinus Pharmaceuticals Inc

Marinus Pharmaceuticals — Investor Presentation (September 2023)

54 slides from Marinus Pharmaceuticals's investor presentation, Sep 28, 2023

  1. Slide 1: Corporate Presentation September 2023

    Nasdaq: MRNS @MarinusPharma Photo Credit: Kelly Crews Photography Ryan (center) Living with CDKL5 deficiency disorder Corporate Presentation September 2023

  2. Slide 2: Forward-looking statements

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I To the extent that statements contained in this presentation are not descriptions of historical facts regarding Marinus, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe ha

  3. Slide 3: Ganaxolone Development Pipeline

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I Ganaxolone Development Pipeline 3 Ganaxolone is a positive allosteric GABAA receptor modulator with a well-defined MOA designed to treat patients suffering from seizure disorders. Ganaxolone is designed to modulate both synaptic and extrasynaptic

  4. Slide 4: Ganaxolone U.S. Market Opportunity

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I 4 ¹Symonds JD 2019 Brain ²Osborne JP, Fryer A, Webb D. Epidemiology of tuberous sclerosis. Ann N Y Acad Sci. 1991;615:125-7. ³DeLorenzo RJ et al. J Clin Neurophysiol. 1995; 12: 316-325 4Kapur et al. N Engl J Med 2019;381:2103-13 5Rossetti and Lowe

  5. Slide 5: ZTALMY (ganaxolone) Marigold Clinical Data & Commercial Launch

    ZTALMY® (ganaxolone) oral suspension CV Marigold Clinical Data & Commercial Launch Not for promotional use

  6. Slide 6: Sustained seizure reductions in Marigold open label extension

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I 6 Reduction in monthly major motor seizure frequency through 2 years of the OLE* Patients who remained in the clinical trial at 2 years experienced sustained reduction in MMSF1 ► Following the pivotal trial, 88 out of 101 patients entered an open-

  7. Slide 7: ZTALMY Performance Metrics Indicate Early Launch Success

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I ZTALMY® Performance Metrics Indicate Early Launch Success 7 Expect ZTALMY® U.S. net product revenues of $5M-$5.2M for the third quarter of 2023 Approximately 140 patients active on therapy Median age of ~9 years old Unique prescriber base of appro

  8. Slide 8: A Comprehensive Commercial Strategy to Grow the ZTALMY Brand

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I A Comprehensive Commercial Strategy to Grow the ZTALMY® Brand Patient identification Activate the caregiver community Focused education to HCPs to establish ZTALMY as the standard of care for CDD seizure management Continuously enhance the patient

  9. Slide 9: Rare Epilepsies Oral Ganaxolone Pipeline

    Rare Epilepsies Oral Ganaxolone Pipeline

  10. Slide 10: Tuberous Sclerosis Complex

    Tuberous Sclerosis Complex “Many individuals with TSC continue to experience uncontrolled seizures despite a cocktail of multiple antiepileptic drugs. Because new options are always needed, the TSC community welcomes clinical evaluation of new epilepsy treatments” - Kari Luther Rosbeck, President &

  11. Slide 11: Tuberous Sclerosis Complex (TSC)

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I 11 Tuberous Sclerosis Complex (TSC) CAUSE • Defect or mutation of TSC1 and/or TSC2 genes INCIDENCE • ~1 in 6,000 live births1 COMMON SYMPTOMS • Seizures, cognitive impairment, behavioral difficulties, skin/kidney/lung abnormalities, etc EPILEPSY I

  12. Slide 12: TSC Phase 2 Trial Results

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I TSC Phase 2 Trial Results 12 * -200 -100 -80 -60 -40 -20 0 20 40 60 80 100 Percent reduction in TSC-associated seizure frequency =median 16.6% Secondary and Exploratory Analyses Primary Endpoint Results: 16.6% median reduction in TSC-associated se

  13. Slide 13: Phase 3 Protocol Refinements Informed by Phase 2

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I Phase 3 Protocol Refinements Informed by Phase 2 13 Phase 3 Slower titration initially, designed to optimize tolerability and improve efficacy No (n=6) Yes (n=17) 0 5 10 15 20 25 30 Somnolence-related AE Percentreduction in TSC-associated seizure

  14. Slide 14: Phase 3 Trial Overview

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I Phase 3 Trial Overview 14 ► Enrollment: ~128 patients, targeting sites in the U.S., Western Europe, Canada, Israel, Australia and China • 90% powered to detect a 25% treatment difference • Statistical significance could be achieved with a treatmen

  15. Slide 15: TrustTSC Patient Experience and Demographics

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I TrustTSC Patient Experience and Demographics 15 *These are preliminary data as of August 2023 and may not be representative of demographics of patients and discontinuation rates upon completion of the TrustTSC Trial Age (mean [min-max]) 15 [2-39]

  16. Slide 16: Addressable Patient Population

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I Addressable Patient Population ~2,000 9.6-11k 40% Highly Refractory CDD Patients TSC Highly Refractory CDD Patients TSC Epileptic TSC Prevalence TSC Refractory TSC CDD 24-28k 60-65% Refractory 40-43k 80-85% Epileptic 50,000 1/6000 incidence CDD: P

  17. Slide 17: Leverage of Existing ZTALMY Infrastructure to TSC

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I Leverage of Existing ZTALMY® Infrastructure to TSC Expected to Yield Significant Return with Modest Expansion 17 17 TSC COMMERCIAL INFRASTRUCTURE Modest increase in field force MARKETING STRATEGY Distinct TSC positioning EXPANDED TARGETS 80% overl

  18. Slide 18: Second Generation Product Development

    Second Generation Product Development

  19. Slide 19: Second Generation Ganaxolone Goals

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I Second Generation Ganaxolone 19 Goals Target Oral Pharmacokinetic Profile Increase efficacy Consistent delivery to achieve target plasma concentration Improve tolerability Optimize PK profile to reduce Cmax-related adverse effects Reduce dosing fr

  20. Slide 20: Phase 1 Single Ascending Dose Study

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I Phase 1 Single Ascending Dose (SAD) Study 20 20 Mean Cmax (ng/mL) Mean AUC0-t (h*ng/mL) 41% 31% 38% 18% 18% 14% Study design Ganaxolone reformulation demonstrated linear kinetics at single doses from 100-1200 mg • Single dose PK study in healthy a

  21. Slide 21: Next Steps: Ganaxolone Reformulation and Prodrug

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I Next Steps: Ganaxolone Reformulation and Prodrug 21 Ganaxolone Prodrug Oral prodrug candidate selected Goals: • Optimize PK parameters for efficacy, tolerability and dosing frequency • Increase absorption (oral), solubility (IV) Preclinical IND-en

  22. Slide 22: Lennox-Gastaut Syndrome Development Pathway

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I Lennox-Gastaut Syndrome Development Pathway 22 MARINUS LGS DEVELOPMENT PLAN LGS CLINICAL TRIAL ENDPOINTS Atonic seizures Felbamate (1993) 1. Drop attacks: tonic/atonic 2. All seizures 3. All seizures excl. atypical absence 4. Seizure severity Topi

  23. Slide 23: Acute Seizure Disorders Intravenous Ganaxolone Pipeline

    Acute Seizure Disorders Intravenous (IV) Ganaxolone Pipeline

  24. Slide 24: Status Epilepticus

    Status Epilepticus

  25. Slide 25: Status Epilepticus Overview

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I Status Epilepticus Overview 25 Status Epilepticus = Condition resulting from either the failure of the mechanisms responsible for seizure termination or from the initiation of mechanisms which lead to: • abnormally prolonged seizures (after time p

  26. Slide 26: PK/PD Well Suited for Acute SE Treatment

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I 26 Pharmacokinetics/Pharmacodynamics Well Suited for Acute SE Treatment Experimental PK – plasma and brain1 Brain and plasma concentration after ganaxolone 3 mg/kg IM in mice Human PD – EEG changes2 EEG bispectral index in healthy volunteers follo

  27. Slide 27: Strategic Approach to SE Clinical Development

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I Strategic Approach to SE Clinical Development 27 1. DeLorenzo RJ Pellock JM Towne AR Boggs JG. Epidemiology of status epilepticus. J Clin Neurophysiol. 1995; 12: 316-325 2. Kapur et al. Randomized Trial of Three Anticonvulsant Medications for Stat

  28. Slide 28: Phase 2 Refractory Status Epilepticus Trial Design

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I Treatment Period Loading Dose Maintenance Taper 28 Phase 2 Refractory Status Epilepticus Trial (RSE) Design • Diagnosis of convulsive or non-convulsive SE • Failed at least one 2nd line IV AED but had not progressed to 3rd line IV anesthetics Bolu

  29. Slide 29: Phase 2 Trial Results Demonstrated Rapid Onset and Durability

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I 29 Phase 2 Trial Results Demonstrated Rapid Onset And Durability of Effect Data presented at AES 2019 AEDs – antiepileptic drugs Cohort No escalation to IV anesthetics within 24 hours from infusion initiation (Primary Endpoint) Status-free through

  30. Slide 30: PK/PD Relationship and Rationale for Target Dose

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I PK/PD Relationship and Rationale for Target Dose 30 30 PK model estimations Vaitkevicius H et al. Intravenous ganaxolone for the treatment of refractory status epilepticus: Results from an open-label, dose-finding, phase 2 trial. Epilepsia. 2022 S

  31. Slide 31: RAISE: Phase 3 Trial in Refractory Status Epilepticus

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I Patient Population Study Treatment RAISE: Phase 3 Trial in Refractory Status Epilepticus 31 *SE, status epilepticus; SRSE, super refractory status epilepticus; IV, intravenous; ASM, antiseizure medication; IV ASMs: fosphenytoin/phenytoin, levetira

  32. Slide 32: Baseline Characteristics of the RAISE Trial

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I Baseline Characteristics of the RAISE Trial* 32 Phase 2 RSE Study (17 patients)1 Phase 3 RAISE Study *This is preliminary RAISE data as of Sept. 2023 and may not be representative of demographics of patients upon full enrollment of the RAISE trial

  33. Slide 33: RAISE Endpoints and Interim Analysis

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I RAISE Endpoints and Interim Analysis 33 OTHER SECONDARY ENDPOINTS §Medications for the acute treatment of SE are defined as ASMs administered to abort ongoing SE or prevent imminent recurrence of SE based on clinical or EEG evidence. This definiti

  34. Slide 34: RAISE II: Phase 3 Trial in Refractory Status Epilepticus

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I RAISE II: Phase 3 Trial in Refractory Status Epilepticus 34 1 Kapur et al. Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus N Engl J Med 2019;381:2103-13. Benzodiazepine Administered IV AEDs (antiepileptic drugs) IV Anes

  35. Slide 35: RESET: Phase 3 Trial in Established Status Epilepticus

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I RESET: Phase 2 Trial in Established Status Epilepticus 1 Kapur et al. Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus N Engl J Med 2019;381:2103-13. Key Trial points: • Patients with convulsive status epilepticus • New

  36. Slide 36: RESET Trial Design in Established Status Epilepticus

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I RESET Trial Design in Established Status Epilepticus 36 Screening <30 min Enrollment Fail BZD IV ganaxolone infusion 1 IV ganaxolone infusion 3 SOC IV AED Convulsive SE (N=40) Ganaxolone bolus Ganaxolone bolus Ganaxolone bolus Seizures YES NO Seiz

  37. Slide 37: Approach to SRSE

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I ► Novel dosing approach and current eINDs • ↓Cmax but ↑ AUC + oral wean • GNX 833mg/day x 48h➛1,050mg/day x 168h • Captisol® 50gm/day ➛63gm/day Approach to SRSE 37 19 patients with SRSE treated to date with IV ganaxolone 14 with similar regimen to

  38. Slide 38: Super Refractory Status Epilepticus: Ganaxolone Experience to Date

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I Super Refractory Status Epilepticus: Ganaxolone Experience to Date 38 New onset refractory status epilepticus (NORSE) Febrile illness-related epilepsy syndrome (FIRES) Lennox-Gastaut syndrome PCDH-19 related epilepsy Autoimmune encephalitis Herpes

  39. Slide 39: Building Commercial Infrastructure for Future IV Launches

    Building Commercial Infrastructure for Future IV Launches

  40. Slide 40: Roadmap to Success in the Hospital Market

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I Roadmap to Success in the Hospital Market 40 40 Charting our own path to deliver a groundbreaking treatment for patients with refractory status epilepticus Market Segmentation & Targeting Robust Total Value Proposition Advanced analytics as a GPS

  41. Slide 41: Outcomes Deteriorate as RSE Progresses

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I Outcomes Deteriorate as RSE Progresses Despite Intensive Levels of Care As SE progresses, healthcare resource utilization increases, but patient outcomes worsen IV anti-seizure meds Medically-induced coma with IV anesthetics Progression to ≥ 3 ASM

  42. Slide 42: Clinical and Healthcare Costs Associated with RSE

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I Clinical and Healthcare Costs Associated with RSE 42 Utilization and Cost Outcomes Metric Cohort 1 (≤ 1 IV AED) Cohort 2 (> 1 IV AED) Cohort 3 (≥ 1 IV anesthetic) All Unique RSE patient encounter, N (%) 14,694 (33.4) 10,140 (23.1) 19,154 (43.5) 43

  43. Slide 43: Financial Update

    Financial Update

  44. Slide 44: Financial Overview

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I Financial Overview 44 Analyst Coverage*: Cantor Fitzgerald: Charles C. Duncan, Ph.D. Cowen: Joseph Thome, Ph.D. H.C. Wainwright & Co: Douglas Tsao Jefferies: Andrew Tsai JMP Securities: Jason N. Butler, Ph.D. Ladenburg Thalmann: Michael Higgins Op

  45. Slide 45: Intellectual Property

    Intellectual Property

  46. Slide 46: Multiple Layers Of Potential Protection

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I Multiple Layers Of Potential Protection 46 Orphan drug designations for CDD and PCDH19 provide 7 and 10 years regulatory exclusivity in U.S. and EU, respectively. Orphan drug designation for SE provides 7 years regulatory exclusivity in U.S. U.S.

  47. Slide 47: Appendix

    Appendix (® MARINUS

  48. Slide 48: Phase 3 CDD Marigold Trial Data and Safety Summary

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I 48 Ganaxolone Placebo 0 10 20 30 40 Median Percent Reduction 28-day Frequency of Major Motor Seizures 30.7% 6.9% *Wilcoxon Rank-Sum Test **Hodges-Lehman Estimate of Median Dif erence Patients taking ganaxolone experienced a significant reduction i

  49. Slide 49: Average Ganaxolone Levels Correlate with Seizure Reduction

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I Average Ganaxolone Levels Correlate with Seizure Reduction 49 • Logarithms of plasma ganaxolone level and percentage change in major motor seizure frequency were negatively correlated • Patients in the Medium and High ganaxolone level groups had a

  50. Slide 50: Details on Baseline Patient Characteristics for Phase 2 RSE Trial

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I 50 Details on Baseline Patient Characteristics for Phase 2 RSE Trial NCSE: Non-convulsive status epilepticus CSE: Convulsive status epilepticus LAC: Lacosamide LEV: Levetiracetam LOR: Lorazepam PHT: Phenytoin fPHT: Fosphenytoin VPA: Valproic Acid

  51. Slide 51: PK/PD Relationship and Rationale for Target Dose

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I 51 PK/PD Relationship and Rationale for Target Dose Modeled PK Curves for All Dose Groups High Dose Achieved Target Range ≥ 500 ng/mL for ~8 hours Only High Dose Provided Sustained Reduction (>80%) Throughout Entire Analysis Window Data presented

  52. Slide 52: RAISE Trial Sites Standard of Care Progression to IV Anesthesia

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I 52 RAISE Trial Sites Standard of Care Progression to IV Anesthesia ► Surveyed PI’s at selected RAISE Trial sites to learn more about their standard of care natural history progression to IV anesthesia following the failure of one versus more than

  53. Slide 53: RAISE Protocol Amended to Accelerate Enrollment

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I RAISE Protocol Amended to Accelerate Enrollment 53 Original Protocol Amended Protocol Patients excluded IF SE would NOT warrant anesthesia for the next 24 hours IV anesthesia would likely be next treatment if study drug (ganaxolone or placebo) doe

  54. Slide 54: Partnership and Non-Dilutive Funding Overview

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I Partnership and Non-Dilutive Funding Overview 54 1 Subject to launch of Ztalmy and continued development and commercialization of ganaxolone 2 Subject to continued development and commercialization of ganaxolone 3 Additional funding of up to ~$18

Marinus Pharmaceuticals — Investor Presentation (September 2023) on 6ix